Delcath: Large Upside With Limited Downside Risk

Company Overview - Delcath (NASDAQ: DCTH) has developed a liver-directed chemotherapy system currently used to treat liver metastatic uveal melanoma [1] - The addressable market for Delcath's treatment is currently small, but the uveal melanoma opportunity is likely sufficient to justify the company's current market capitalization [1] Investment Strategy - Narweena, an asset manager led by Richard Durant, focuses on identifying market dislocations due to poor understanding of long-term business prospects [2] - The firm aims to achieve excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with barriers to entry [2] - Narweena's research emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and long-term investment horizon [2] Market Dynamics - An aging population with low growth and stagnating productivity is expected to create a different set of investment opportunities compared to the past [2] - Many industries may face stagnation or secular decline, which could paradoxically enhance business performance as competition decreases [2] - Conversely, some businesses may encounter rising costs and diseconomies of scale [2] - The economy is increasingly dominated by asset-light businesses, leading to a declining need for infrastructure investments over time [2] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [2]